➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Patent: 10,329,246

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,329,246
Title:RUNX2 transcription factor inhibitors and uses thereof
Abstract: Provide herein are compounds with a general chemical structure of: ##STR00001## Substituents R.sub.1 and R.sub.2 independently are H, Cl, F, Br, CH.sub.3, CF.sub.3, SH, --N(C.sub.1-3alkyl).sub.2, --NHC(O)C.sub.1-3alkyl, or --NHC(O)C.sub.5-7cycloalkyl, substituent R.sub.3 is H or C.sub.1-3 alkyl and R4 is a bridged cycloalkene such as a bridged cyclohexene or a bridge-substituted cyclohexene. The compounds are therapeutics to treat a cancer, such as breast cancer, or metastatic cancers, to inhibit RUNX2 activity, such as protein expression, in a cancer cell and to increase survival of a subject with breast cancer.
Inventor(s): Passaniti; Antonino (White Hall, MD), Alexander, Jr.; MacKerell D. (Baltimore, MD)
Assignee: University of Maryland, Baltimore (Baltimore, MD) The United States of America as represented by the Department of Veterans Affairs (Washington, DC)
Application Number:15/708,872
Patent Claims:see list of patent claims

Details for Patent 10,329,246

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial University of Maryland, Baltimore (Baltimore, MD) The United States of America as represented by the Department of Veterans Affairs (Washington, DC) 2035-03-19 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.